Most sites never see the scorecard that decides whether they get the next study, but that scorecard exists.
November 6, 2026
7
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
The ranking happens whether you see it or not
After every study, and often during it, a sponsor builds a picture of each site. Some of it lives in formal performance systems. Some lives in the working memory of clinical operations teams: who answered feasibility honestly, who activated without drama, who enrolled the patients they promised, and who created extra work for monitors.
That picture follows you: into the next feasibility round, onto a preferred site list, or out of both. Geography, therapeutic experience, and relationships open the door. Measured performance keeps it open — and the metrics are the same handful, tracked study after study.
Enrollment velocity against commitment
The first measure is not raw enrollment. It is enrollment against your own commitment.
Before activation, a site tells the sponsor how many patients it expects to screen and randomize, and over what period. Sponsors record that forecast. A site that commits conservatively and delivers on time will usually outrank one that promises twice as many and delivers half, even if the second randomized more people overall.
The reason is planning. A sponsor builds its timelines, drug supply, and budget around site forecasts. A missed forecast forces rescue sites and timeline extensions. A met forecast, even a modest one, makes the sponsor's planning work.
Make forecasts you can defend from your own records. Count eligible patients conservatively, account for competing studies and staff capacity, and update the sponsor early if conditions change. Early honesty damages a ranking far less than silence, then a missed commitment.
Startup speed
Sponsors measure how long a site takes from selection to activation: contract and budget negotiation, institutional review board (IRB) approval, essential documents, site initiation, and readiness to screen.
Speed matters, but not at any cost. What sponsors value is a predictable startup: documents returned complete the first time, a principal investigator (PI) who is available for required meetings and signatures, and a team that answers contracting questions without long gaps.
Treat startup as a defined workflow under your standard operating procedure (SOP) framework, with a named owner for each step. Most delay is not scientific. It is waiting: for a signature, a certificate, or a document no one realized was missing.
Screen-failure discipline
Screening activity looks like productivity, but sponsors look closer. They track how many patients are screened relative to how many enroll, and whether decisions follow the protocol's eligibility criteria.
A high screen-failure rate is not automatically a failure. Some protocols, especially in early-phase and device research, have strict criteria that legitimately exclude many candidates. What concerns sponsors is undisciplined screening: patients who clearly do not meet basic criteria, incomplete pre-screening, or eligibility questions raised only after expensive procedures.
Disciplined sites pre-screen carefully against the inclusion and exclusion criteria before the formal screening visit, document why candidates were excluded, and ask eligibility questions before screening, not after. That protects patients and the budget, and signals that the site understands the protocol.
Data quality: queries and protocol deviations
Enrollment gets a site noticed. Data quality decides trust.
Sponsors and CROs track the number and pattern of data queries from a site's entries in the electronic data capture (EDC) system, the rate of protocol deviations, and whether errors repeat after being addressed. Occasional queries are normal. Patterns matter: missing fields, inconsistent dates, source documents that do not match database entries, or repeated deviations in the same procedure.
A single well-documented deviation, reported promptly, with a corrective and preventive action (CAPA) plan, demonstrates a functioning quality culture. Repeated deviations of the same type, discovered by a monitor rather than reported by the site, suggest the opposite.
Sites that rank well treat source documentation as the product, not paperwork after it. They build self-checks into visit workflows and close the loop when a pattern appears.
Query turnaround time
From the sponsor's side, open queries are unfinished work. They block database cleaning, interim analyses, and ultimately database lock. A site can have excellent enrollment and still become a bottleneck if queries sit unanswered for weeks while the rest of the program waits.
Responsiveness is a habits question. Someone should own query review on a regular cadence, not as an end-of-study project, and the PI should be available for queries requiring medical judgment. Sponsors record which sites clean data continuously and which need repeated escalation.
Retention through the last visit
A participant who withdraws early delivers only part of the planned value, and in smaller early-phase studies a few withdrawals can materially affect what the data can show. Sponsors therefore track retention: how many enrolled participants complete the required visits and procedures.
Retention is partly protocol burden and partly site craft. Sites that perform well set expectations honestly at consent, schedule around patients' real lives where the protocol allows, communicate between visits, and surface problems — transportation, scheduling conflicts, burden — while they can still be solved. Flagging a struggling participant early gives the sponsor a chance to help; reporting a withdrawal after the fact gives only a lost data point.
What recognition programs actually reward
Many sponsors and larger CROs run formal site recognition programs: awards, preferred site designations, and public acknowledgments of high-performing sites. Sites sometimes wonder whether these are marketing exercises or rewards for personal relationships.
Structurally, they are neither. Recognition programs exist because sponsors need high-performing sites to say yes to the next study, and public recognition helps retain them. The criteria track the measures above: enrollment against commitment, startup timelines, data quality, well-managed deviations, responsiveness, and retention. A clean audit history reinforces the case. At Amavita Research Services, we maintain a database of more than 18,000 active cardiology patients and a record of zero Food and Drug Administration (FDA) Form 483 findings — but neither fact, on its own, earns anything. What matters is whether that infrastructure converts, study after study, into the delivery measures on the scorecard.
Absent from that list: booth traffic, sponsored dinners, social visibility, and personal familiarity. Relationships can get a site considered. They do not substitute for the data behind it.
How a site earns its way onto them
There is no application strategy that bypasses performance. Sites earn recognition the slow way, through a pattern a sponsor can verify:
- Answer feasibility honestly and quickly. A fast, realistic response — including a candid "we are not the right site for this protocol" — builds more credibility than an optimistic answer given to win selection.
- Deliver consistently across studies, not once. One strong study makes a site promising. A second and third, including a difficult one, make it preferred.
- Keep audits and monitoring visits boring. Complete files, traceable source data, and deviations self-reported with CAPA plans are the substance behind a clean quality reputation.
- Be easy to work with between milestones. Feasibility answers, contract comments, and status updates all feed the same judgment: this site responds, accurately, without being chased.
- Protect the record when a study goes badly. Protocols fail and sponsors know it. Sites that communicate early and document what they did protect their ranking even when a study underperforms.
The bottom line
Sponsors rank sites on evidence: enrollment against commitment, startup speed, screen-failure discipline, data quality, query turnaround, and retention. Recognition programs reward that same evidence, formalized. A site that wants to be preferred does not need a better pitch. It needs a track record, visible in the sponsor's own systems, of promising carefully, starting predictably, documenting cleanly, and finishing what it starts. Build the habits that produce those numbers, and recognition tends to follow — because that is precisely what it was designed to measure.
*Julio G. Martinez-Clark is CEO of bioaccess® and of Amavita Research Services, a Miami cardiovascular trial site.*
Julio G. Martinez-Clark is chief executive officer (CEO) of bioaccess\u00AE, a first-in-human contract research organization running early-phase trials anywhere from Canada down to Argentina, and of Amavita Research Services, a Miami cardiovascular research site he has operated for seven years with zero United States Food and Drug Administration (FDA) Form 483 inspection findings. He founded Global Trial Accelerators\u2122, a podcast for medtech and biotech founders navigating first-in-human studies.